Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXAYDO vs ANHYDRON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxycodone is a full opioid agonist with relative selectivity for mu-opioid receptors, although it can bind to kappa-opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect to analgesia for oxycodone.
Inhibits the sodium-potassium-2 chloride (Na-K-2Cl) cotransporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.
Management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate
Edema associated with congestive heart failure, cirrhosis of the liver, and renal disease,Hypertension (off-label use)
Oral, 5-10 mg every 4-6 hours as needed for pain; maximum 60 mg per day.
Oral: 25-100 mg once daily in the morning, or 50-100 mg every other day; maximum 200 mg/day.
Terminal elimination half-life is 3.5-5.5 hours for immediate-release oxycodone; clinically dose every 4-6 hours for sustained analgesia.
Terminal elimination half-life is 60-90 minutes, prolonged in renal impairment (up to 24 hours).
Primarily hepatic via CYP3A4 and CYP2D6; major metabolites include noroxycodone (via CYP3A4) and oxymorphone (via CYP2D6). Conjugated with glucuronic acid.
Partially metabolized by the liver; primarily excreted unchanged in urine.
Primarily renal as unchanged drug and metabolites; ~90% excreted in urine (approx 10% unchanged oxycodone, rest as noroxycodone and oxymorphone conjugates) and <10% in feces via biliary elimination.
Renal: ~60% unchanged; biliary/fecal: ~40% as metabolites and unchanged drug.
~45% bound to plasma proteins, primarily albumin.
95% bound, primarily to albumin.
2.6 L/kg; indicates extensive tissue distribution.
0.2-0.3 L/kg, reflecting distribution primarily in extracellular fluid.
Oral bioavailability is 60-87% due to first-pass metabolism.
Oral: ~65% (range 50-80%) due to first-pass metabolism.
Cr Cl <30 m L/min: reduce dose by 50% and extend dosing interval to every 6 hours; avoid use in Cr Cl <15 m L/min.
GFR 10-50 m L/min: 50 mg every 12 hours. GFR <10 m L/min: 50 mg every 24 hours or not recommended.
Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: avoid use.
Mild to moderate hepatic impairment (Child-Pugh A or B): no adjustment. Severe hepatic impairment (Child-Pugh C): avoid use.
Children (≥11 years): 5-10 mg every 4-6 hours as needed; maximum 60 mg/day. Children <11 years: not recommended due to high concentration.
1-2 mg/kg/dose once daily; maximum 100 mg/day.
Initiate at 3 mg every 6 hours; titrate cautiously due to increased sensitivity and risk of respiratory depression.
Start at 12.5-25 mg once daily; titrate slowly due to risk of hypotension and electrolyte imbalance.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS. See full prescribing information for complete boxed warning.
No FDA black box warning.
Addiction, abuse, and misuse,Life-threatening respiratory depression,Accidental ingestion (especially in children),Neonatal opioid withdrawal syndrome,Risks from concomitant use with benzodiazepines or other CNS depressants,Adrenal insufficiency,Severe hypotension,Gastrointestinal effects (constipation, ileus),Seizures in patients with seizure disorders,Serotonin syndrome with concomitant serotonergic drugs
Electrolyte imbalance (hypokalemia, hyponatremia, hypochloremia),Dehydration and hypotension,Ototoxicity (especially with rapid IV administration or renal impairment),Hyperuricemia and gout,Sulfonamide cross-sensitivity in sulfa-allergic patients
Hypersensitivity to oxycodone or any component of the formulation,Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus
Anuria,Severe renal failure,Hepatic coma or pre-coma,Severe electrolyte depletion,Hypersensitivity to sulfonamides
Take OXAYDO on an empty stomach for consistent absorption; high-fat meals increase peak concentration by 25% and delay Tmax by 0.5-1 hour. Avoid grapefruit juice (inhibits CYP3A4) as it may elevate oxycodone levels.
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, spinach) as hyperkalemia may occur. Limit salt substitutes containing potassium. Grapefruit juice may increase drug absorption; avoid concurrent use. Alcohol may enhance orthostatic hypotension.
Pregnancy Category C. First trimester: Limited human data; animal studies show increased risk of neural tube defects at high doses. Second and third trimesters: Prolonged use may cause neonatal opioid withdrawal syndrome and respiratory depression. No specific teratogenicity pattern identified in humans.
Cyclothiazide (ANHYDRON) is a thiazide diuretic. Use in pregnancy is generally avoided due to potential adverse effects. First trimester: limited data, but thiazides have been associated with an increased risk of congenital anomalies in some studies, including cleft lip/palate and cardiac defects. Second and third trimesters: can cause fetal or neonatal jaundice, thrombocytopenia, electrolyte disturbances, and possibly intrauterine growth restriction. Crosses the placenta. Use only if clearly needed for maternal conditions like hypertension or edema.
Enters breast milk; no specific M/P ratio reported. Use caution due to risk of infant sedation and respiratory depression. Monitor for signs of toxicity; alternative analgesics preferred.
Cyclothiazide is excreted into human breast milk. The milk-to-plasma ratio is not well defined for cyclothiazide but for thiazides generally is around 0.5-1.0. May suppress lactation. Potential for infant adverse effects (e.g., electrolyte disturbances, thrombocytopenia). Use caution in breastfeeding; alternatives are preferred.
No specific dose adjustment recommended for pregnancy; increased clearance in second/third trimester may necessitate dose increase for adequate analgesia. Use lowest effective dose, avoid prolonged use; taper near term to minimize neonatal withdrawal.
Pharmacokinetic changes in pregnancy (increased plasma volume, renal blood flow, and GFR) may reduce effectiveness of thiazides. No specific dosing adjustment guidelines for cyclothiazide; however, if used, start at lowest effective dose and titrate based on response. Typical adult dose: 2 mg once daily; may adjust to 1-4 mg. Monitor for hypotension and electrolyte imbalances. Avoid in preeclampsia due to decreased placental perfusion.
OXAYDO is a single-entity oxycodone oral solution designed for rapid absorption; bioavailability is ~60-87% higher than oxycodone tablets due to high intestinal permeability. It is contraindicated with CYP3A4 inhibitors (e.g., ketoconazole) which can increase oxycodone levels. Monitor for respiratory depression, especially in opioid-naive patients. Each m L contains 7.5 mg oxycodone HCl, equivalent to 6.5 mg oxycodone base. Use with caution in patients with renal impairment (Cr Cl <30 m L/min).
ANHYDRON (cyclothiazide) is a thiazide-like diuretic used for hypertension and edema. Monitor serum potassium and glucose levels; hypokalemia and hyperglycemia are common. Use with caution in renal impairment (Cr Cl <30 m L/min). Avoid in patients with anuria or sulfonamide allergy.
Take OXAYDO exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they increase risk of severe drowsiness, respiratory depression, coma, or death.,Do not drive or operate heavy machinery until you know how OXAYDO affects you; may cause dizziness or drowsiness.,Store securely away from children and pets; accidental ingestion can be fatal.,Do not crush, chew, or dissolve the capsules; swallow whole to avoid rapid release and overdose.,Report any difficulty breathing, confusion, or excessive sedation to your healthcare provider immediately.
Take exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,May cause dizziness or lightheadedness; rise slowly from sitting or lying down.,Avoid prolonged sun exposure; use sunscreen as photosensitivity may occur.,Report signs of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat.,Do not stop abruptly without consulting your doctor; gradual dose reduction may be needed.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXAYDO vs ANHYDRON, answered by our medical review team.
OXAYDO is a Opioid Analgesic that works by Oxycodone is a full opioid agonist with relative selectivity for mu-opioid receptors, although it can bind to kappa-opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect to analgesia for oxycodone.. ANHYDRON is a Thiazide Diuretic that works by Inhibits the sodium-potassium-2 chloride (Na-K-2Cl) cotransporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXAYDO and ANHYDRON depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXAYDO is: Oral, 5-10 mg every 4-6 hours as needed for pain; maximum 60 mg per day.. The standard adult dose of ANHYDRON is: Oral: 25-100 mg once daily in the morning, or 50-100 mg every other day; maximum 200 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXAYDO and ANHYDRON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXAYDO is classified as Category C. Pregnancy Category C. First trimester: Limited human data; animal studies show increased risk of neural tube defects at high doses. Second and third trimesters: Prolonged use may c. ANHYDRON is classified as Category C. Cyclothiazide (ANHYDRON) is a thiazide diuretic. Use in pregnancy is generally avoided due to potential adverse effects. First trimester: limited data, but thiazides have been asso. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.